Autopsy report · NCT02215876

Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer

“No patients recruited.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Sponsor type

University, hospital or other

Conditions

Breast Cancer

Interventions

Doxorubicin; Cyclophosphamide; Eribulin

Participants

0

Sites

1

Countries

Singapore

Trials that died the same way

• Use of the INAMED LAPBAND System to Reduce BMI's in Obese Renal Failure Patients
  “No patients were enrolled.” (89% match in meaning)
• Energy Expenditure and Gastric Bypass Surgery
  “no patients enrolled.” (89% match in meaning)
• Tolerability, Safety and Activity of a Muscle Relaxant Molecule IDN5243 in Patients With Low Back Pain
  “No patients enrolled in the study.” (87% match in meaning)
• Effect of Intensive Cognitive Rehabilitation on Cognitive, Motor, and Language Functional Networks in Subacute Stroke Patient
  “Patients not recruited.” (87% match in meaning)
• Effects of Atomized Dexmedetomidine on Lung Function in Patients With Chronic Obstructive Pulmonary Disease
  “no patient enrolled.” (87% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.